Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Jetstar to Charge for Overhead Cabin Bags From February 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
NEW DELHI, India, March 12, 2018 -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announces that N. Venkat, chief executive officer and co-founder of Vyome Biosciences, will present at the Cowen and Company 38th Annual Health Care Conference at 11:30 a.m. EDT on Tuesday, March 13, 2018, at the Boston Marriott Copley Plaza, Boston.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
[email protected]
